Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

Trial Profile

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jan 2022 Results of an analysis to compare the immunogenicity of using BNT162b2 and CoronaVac as a third dose for adults with low antibody response to two doses of CoronaVac published in the American Journal of Respiratory and Critical Care Medicine
    • 24 Nov 2021 Results published in the Respirology
    • 17 Aug 2021 Number of treatment arms have been increased from 3 to 5. The previous arms of antipyeritic, remdesivir, interferon, ribavirin and lopinavir/ ritonavir 400mg/100mg (Kaletra) have been removed and replaced by CoronaVac vaccine and BionTech vaccine arms. Time frame for primary end-point measurement is increased from 2 to 3 years.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top